WuXi Apptec WKN: A2PAJG ISIN: CNE100003F19 Kürzel: WX8 Forum: Aktien User: Summer.76

Morgan Stanley: Upgrading WuXi AppTec's (02359) target price to HK$187, rating "overweight" https://m.jrj.com.cn/madapter/hk/2021/04/15102132377985.shtml Morgan Stanley released a research report that raised the target price of WuXi AppTec (02359) from HK$178 to HK$187, with a rating of “overweight”. According to the report, taking into account the company’s performance in the second half of last year and the rapid recovery of production orders in various regions, it raised its 2021-24 profit forecast by about 8% to 9%, and raised the company’s capital expenditure forecast. , WuXi AppTec's production demand will greatly increase.

https://www.businesswire.com/news/home/20210407005162/en/Endevica-Bio-Begins-IND-Enabling-Toxicology-Studies

Etwas länger und ein Fall für den Übersetzer: Die Leistung von WuXi AppTec im Jahr 2020 steigt um fast 60%, die Bestellungen steigen weiter, das Kapital steigt weiter https://wap.stockstar.com/detail/IG2021040100000703

Das klingt doch alles ganz gut

WuXi AppTec (02359 HK) proposes to issue a final dividend of 36.3 cents for every 10 shares to increase by 2 shares https://www.finet.hk/newscenter/news_content/60638ecfbde0b335eab748ee WuXi AppTec (02359 HK) announced its annual results for the year ended December 31, 2020. During the period, revenue was 16.535 billion yuan (RMB. The same below), an increase of 28.46%; profit was 2.96 billion yuan, Year-on-year increase of 59.62%, earnings per share of 1.27 yuan; a final dividend of 36.3 cents per share is recommended, and 2 shares for every 10 shares.   ... FINAL DIVIDEND AND CONVERSION OF RESERVE TO SHARE CAPITAL The Board proposes the profit distribution plan for the year ended December 31, 2020 as follows: (i) a cash dividend of RMB3.63 (inclusive of tax) for every 10 shares (representing an aggregate amount of RMB889,537,206.36 (inclusive of tax) based on the total issued share capital of the Company as of the date of this announcement), and (ii) 2 new Shares for every 10 existing Shares of the Company to be issued out of reserve to all Shareholders.  ...

https://www.finanzen.net/nachricht/aktien/wuxi-apptec-bilanzvorlage-zum-letzten-quartal-9970658

WuXi AppTec Reports Strong 2020 Annual Results https://www.prnewswire.com/news-releases/wuxi-apptec-reports-strong-2020-annual-results-301258546.html Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year to RMB3,565 Million Adjusted Diluted Non-IFRS EPS Up 45.2% Year-over-Year to RMB1.51

https://www.finanzen.net/nachricht/aktien/ausblick-wuxi-apptec-a-legt-quartalsergebnis-vor-9961400

[Changes in equity] WuXi AppTec (02359-HK) obtains BlackRock's increase of 383,600 shares https://www.finet.hk/newscenter/news_content/605240958ac02a2a289d315f According to the equity information of the Hong Kong Stock Exchange, WuXi AppTec (02359-HK) won BlackRock on March 12 to increase its holdings of 383,600 shares at an average price of HK$153.3883 per share, involving approximately 5,839,98 Ten thousand Hong Kong dollars. After the increase, BlackRock's latest shareholding number is 34,704,400 shares, and the shareholding ratio has increased from 10.88% to 11.00%. (Source: FinetAI)

WuXi AppTec Co Ltd. -- Moody's revises WuXi AppTec's outlook to positive; Baa3 rating affirmed https://finance.yahoo.com/news/wuxi-apptec-co-ltd-moodys-100306021.html

UBS: WuXi AppTec (02359). Wiederholt das "Kaufen"-Rating und hebt das Kursziel um 69% auf HK $ 232 an https://m.jrj.com.cn/madapter/hk/2021/03/08135532090915.shtml Die Zhitong Finance App erfuhr, dass UBS einen Research-Bericht veröffentlicht hat, in dem sie aufgrund der starken Rentabilität von WuXi AppTec (02359) das Kursziel um 69% von 137 HK $ auf 232 HK $ erhöhte, das Kaufrating wiederholte und den Nettogewinn 2021-24 erhöhte Prognose 8-18%. In dem Bericht wurde erwähnt, dass aufgrund der besser als erwarteten Geschäftsaussichten der biomedizinischen F & E-Outsourcing-Branche in China das Geschäft während der Epidemie globale Marktanteile gewann und Chinas technische und technologische Vorteile voraussichtlich weiterhin den globalen Marktzugang zu Chinas CRO-Führern erhalten werden nach der Epidemie Share. Das erwartete Kurs-Gewinn-Verhältnis von WuXi AppTec in diesem Jahr beträgt das 84-fache und liegt damit unter dem Durchschnitt der wachstumsstarken Kollegen und des 180-fachen von WuXi Biologics (02269). Der Transaktionspreis liegt unter dem Durchschnitt der wachstumsstärksten Wettbewerber, was darauf hinweist, dass der Markt sein langfristiges Wachstum nicht berücksichtigt.  ...

WuXi AppTec schließt die Übernahme von OXGENE ab und baut damit das Serviceangebot für Zell- und Gentherapie für globale Kunden weiter aus https://www.finanzen.net/nachricht/aktien/wuxi-apptec-schliesst-die-uebernahme-von-oxgene-ab-und-baut-damit-das-serviceangebot-fuer-zell-und-gentherapie-fuer-globale-kunden-weiter-aus-9872219

Der Artikel befasst sich mit den Anpassungen der Fondsmanager im Jahr des Ochsen und wurde noch vor Börsenstart heute veröffentlicht. Ist relativ lang und deshalb bei Bedarf eigenständig durch den Übersetzer jagen: https://m.jrj.com.cn/madapter/fund/2021/02/22050532002328.shtml ...  During the Spring Festival, some celebrity fund managers and wealth management celebrities took their *** and launched a series of online wealth management live broadcasts to compete with various “net celebrities”. On the first trading day of the Year of the Ox, the core assets of the public fund Baotuan performed poorly. Affected by the substantial adjustment of core assets, many funds' single-day performance fell even more than stocks, and individual funds fell into the "hot search" again. ... The main reason is that the fund group stocks that have gained too much in the previous period have undergone a large adjustment, and the fund holdings represented by Kweichow Moutai have undergone a large adjustment. On February 18, Kweichow Moutai plunged 5% in a single day, the market value evaporated over 160 billion yuan, and many leading liquor stocks fell collectively. Pharmaceutical stocks represented by WuXi AppTec (Hong Kong Stock 02359) also experienced collective adjustments. WuXi AppTec fell more than 7% in a single day,...

WuXi AppTec (02359) hat 2.681.700 H-Aktien auf Basis von Wandelanleihen ausgegeben https://m.jrj.com.cn/madapter/hk/2021/02/18163831987041.shtml WuXi AppTec (02359), gab eine Ankündigung zur Umwandlung und Ausgabe von 2.681.700 H-Aktien auf der Grundlage von USD 300 Millionen Nullkupon-Wandelanleihen mit einer Laufzeit bis 2024 bekannt.

Quanterix Announces Simoa Joint Laboratory with WuXi AppTec https://www.biospace.com/article/releases/quanterix-announces-simoa-joint-laboratory-with-wuxi-apptec-/ ...today announced it has entered into an agreement to open a joint Simoa laboratory with WuXi AppTec to improve access to Quanterix’ industry leading biomarker testing and development offerings across China and the APAC market. ... “Biomarkers are proving essential to the future of disease research and drug development, making it imperative that research organizations across the globe have access to the best possible tools and resources for study,” said Dr. Steve Yang, Co-Chief Executive Officer, WuXi AppTec. “Quanterix continues to demonstrate dominance in this area with its Simoa platforms and assays. We have a strong belief that this partnership, coupled with WuXi AppTec’s open-access enabling platform, especially in the clinical bioanalytical field, will provide comprehensive solutions to our customers in greater China and APAC to drive important advances in disease detection, treatment, and ultimately, prevention.”

Die in den USA notierte Beteiligungsgesellschaft von WuXi AppTec (02359-HK) https://m.jrj.com.cn/madapter/hk/2021/02/10190531884401.shtml WuXi PharmaTech (02359-HK) gab bekannt, dass die Beteiligungsgesellschaft des Unternehmens, Adagene, am 9. Februar 2021 (US-Zeit) an der Nasdaq Stock Exchange mit dem Aktiencode ADAG notiert wird. Nach Abschluss des weltweiten Angebots von Adagene hält das Unternehmen 5.356.946 Aktien von Adagene, was nach der Emission von Adagene etwa 10,16% des gesamten Aktienkapitals entspricht.